The emergence of positive data from trials like PATINA creates a dilemma for oncologists treating patients who are already stable on an older maintenance therapy. The consensus suggests not altering a successful regimen to avoid disrupting patient stability, revealing a cautious approach to integrating new evidence into established care.

Beyond overall response rates, a critical area of excitement for new ADCs in lung cancer is their potential to treat brain metastases. Early data showing hints of intracranial efficacy is a significant point of interest, as this addresses a common and difficult-to-treat site of disease progression, offering a potential advantage over other therapies.

While lurbinectedin initially improves survival outcomes as maintenance therapy, long-term data shows the survival curves eventually converge. Experts interpret this to mean the drug provides a temporary, additive chemotherapy-like effect rather than a true synergy with immunotherapy that would produce a durable response and separate the "tails of the curves."

The IMFORTE trial saw a 25% attrition rate between induction and randomization for maintenance therapy. This reflects the clinical reality that a significant portion of patients are too debilitated by initial chemo-IO to be candidates for intensified maintenance, making immunotherapy alone a reasonable alternative for them.

The MFORTE trial revealed a significantly higher rate of brain-only progression in the lurbinectedin arm (27% vs 10%). This pattern suggests the drug's effective systemic control and lack of CNS penetration combine to unmask the brain as a primary sanctuary site for relapse over time.

When EGFR+ NSCLC transforms to small cell, clinicians often continue the TKI osimertinib alongside chemotherapy. This practice is largely based on expert consensus and the rationale of suppressing any remaining EGFR-driven clones, rather than on definitive clinical trial data showing a clear benefit.

Despite acknowledging that a one-size-fits-all treatment duration is suboptimal, the expert consensus is to follow the study protocol. This conservative, evidence-based approach prevails due to the absence of validated biomarkers, like ctDNA, to safely guide treatment de-escalation for individual patients.

An expert questions the utility of PCI, arguing that historical studies supporting its use were flawed because they lacked baseline brain MRIs. This means many patients may have been treated for existing, not prophylactic, metastases. Modern MRI surveillance may be a better approach to avoid long-term radiation toxicity in survivors.

In the MFORTE trial, the survival curves for the lurbinectedin-atezolizumab arm eventually converge with the atezolizumab-only arm. This indicates the combination provides an additive benefit (delaying progression) rather than true synergy, which would have created a more durable, long-term survival advantage.